Login to Your Account

Amylin Shares Jump on NDA but Drug Class Concerns Linger

By Catherine Hollingsworth

Wednesday, May 6, 2009
San Diego-based Amylin has filed for regulatory approval of once weekly exenatide for diabetes, causing a slight jump in its shares and the shares of its partners, Alkermes and Eli Lilly and Co. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription